First-line treatment of patients with metastatic pancreatic cancer: Results of a Phase II trial with S-1 (CESAR-Study group)

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 7, 2010, Pages 470-472

  Strumberg, D ^a   Bergmann, L ^b   Graeven, U ^c   Hanauske, A ^d   Lipp, R ^e   Schuette, J ^f   Schultheis, B ^a   Scigalla, P ^g   Urrea, P ^g   Scheulen, M E ^h  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c KLINIKEN MARIA HILF GMBH   (Germany)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f MARIEN HOSPITAL DÜSSELDORF   (Germany)

^g TAIHO   (United States)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

First line; Metastatic disease; Pancreatic cancer; Phase II clinical trial; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; KARNOFSKY PERFORMANCE STATUS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PAIN ASSESSMENT; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SEPSIS; SIDE EFFECT; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

EID: 77954922535     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48470     Document Type: Conference Paper

References (10)

1. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008; 61: 615-621.
2. Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin. 2008; 58: 71-96.
3. Kuramochi H, Hayashi K, Uchida K, Nakajima G, Hatori T, Danenberg KD, Danenberg PV, Yamamoto M. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer Chemother Pharmacol. 2008; 63: 85-89.
4. Lee GW, Kim HJ, Ju JH, Kim SH, Kim HG, Kim TH, Kim HJ, Jeong CY, Kang JH. Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009; 64: 707-713.
5. Monden M. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res. 2008; 28: 179-186. (Pubitemid 351362899)
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff, RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: Aphase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-1966. (Pubitemid 46972777)
7. Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009; 63: 313-319.
8. Nakahira S, Nakamori S, Tsujie M, Takeda S, Sugimoto K, Takahashi Y, Okami J, Marubashi S, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res. 2008; 28: 179-186. (Pubitemid 351362899)
9. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Brit J Cancer. 2006; 94: 1575-1579. (Pubitemid 43924916)
10. Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ, Kim YH. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol. 2010; 65: 527-536.